HB-086 and HB-097 for Treatment of Chronic Sensory Neuronal Disorders - Neuropathic Pain and Hearing Loss

HB-086 and HB-097 comprise our portfolio of therapeutic proteins.

They are a family of growth factors with actions on sensory nerve cells and represent a novel treatment approaches and a paradigm shift for medical treatment and prevention of severe, chronic conditions as pain and hearing loss. The drug candidates target sensory nerve cells and their support cells in dorsal root ganglia and inner ear.

Evidence indicate a mode of action including normalisation of impaired neuronal-glial crosstalk, protection, and regeneration of sensory nerve fibres.

All key biological mechanisms underpinning increased peripheral afferent drive associated with chronic pain, and apoptotic hearing loss.

Preclinical data confirm that HB-086 completely abolishes pain sensation across different models and HB-097 preserves the sense of hearing in relevant models.

Importantly, documented prolonged effects warrant biweekly or monthly dosing and prevention of further disease progression.